Pharmaceutical Privately-held Swiss firm Helsinn Group and partner Japan’s Ono Pharmaceutical received manufacturing and marketing approval of Adlumiz (anamorelin hydrochloride) tablet 50mg, a ghrelin receptor agonist, for the treatment of cancer cachexia in malignant tumors of non-small cell lung cancer, gastric cancer, pancreatic cancer or colorectal cancer in Japan. 22 January 2021